Loading... Please wait... Loading... Please wait...
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
Fresh Tracks Therapeutics, Inc., a clinical-stage pharmaceutical company, engages in the development of various prescription therapeutics for the treatment of autoimmune, inflammatory, and other debilitating diseases in the United States. The company develops sofpironium bromide, which has completed Phase III clinical trials for the treatment of primary axillary hyperhidrosis; BBI-02, an oral DYRK1A inhibitor for the treatment of autoimmune and inflammatory diseases; and BBI-10, a covalent stimulator of interferon genes inhibitor for the potential treatment of autoinflammatory and rare genetic diseases, as well as next-generation kinase inhibitors. It has license and collaboration agreements with Carna Biosciences, Inc., Voronoi Inc., Bodor Laboratories, Inc. and Dr. Nicholas S. Bodor, and AnGes, Inc. The company was formerly known as Brickell Biotech, Inc. and changed its name to Fresh Tracks Therapeutics, Inc. in September 2022. Fresh Tracks Therapeutics, Inc. was founded in 2009 and is headquartered in Boulder, Colorado.
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
Company filed an answer in overall agreement with petition on June 14, 2024 and awaits a hearing date from the Delaware Chancery Court Company filed an answer in overall agreement with petition on Jun...
Stockholders of record on January 11, 2024 who have not yet voted are encouraged to do so by 11:59 p.m. Eastern Time on February 14, 2024...
New record date expected to be January 11, 2024 Company intends to seek judicial dissolution if the liquidation and dissolution is not approved by Fresh Tracks' stockholders at new special meeting, wh...
BOULDER, Colo., Dec. 19, 2023 (GLOBE NEWSWIRE) -- Fresh Tracks Therapeutics, Inc. (OTC Pink: FRTX) (“Fresh Tracks” or the “Company”) announced today that the Company's common stock was suspend...
Common stock expected to begin trading on over-the-counter market following suspension Common stock expected to begin trading on over-the-counter market following suspension...
Meeting adjourned to December 27, 2023 at 10 a.m. MT...
Meeting adjourned to December 15, 2023 at 10 a.m. MT...
Meeting adjourned to November 30, 2023 at 10 a.m. MT Fresh Tracks encourages all stockholders of record on October 17, 2023 who have not yet voted to do so by 11:59 p.m....
Cash and cash equivalents of approximately $11.5 million as of October 31, 2023 Special meeting of stockholders on November 16 seeking stockholder approval of the Dissolution and Plan of Dissolution ...
